Advertisement
Singapore markets closed

  • Straits Times Index

    3,322.62
    +14.72 (+0.45%)
     

  • S&P 500

    5,307.01
    -14.40 (-0.27%)
     

  • Dow

    39,671.04
    -201.95 (-0.51%)
     

  • Nasdaq

    16,801.54
    -31.08 (-0.18%)
     

  • Bitcoin USD

    69,772.06
    -200.96 (-0.29%)
     

  • CMC Crypto 200

    1,502.19
    -0.47 (-0.03%)
     

  • FTSE 100

    8,373.37
    +3.04 (+0.04%)
     

  • Gold

    2,364.20
    -28.70 (-1.20%)
     

  • Crude Oil

    77.77
    +0.20 (+0.26%)
     

  • 10-Yr Bond

    4.4340
    +0.0200 (+0.45%)
     

  • Nikkei

    39,103.22
    +486.12 (+1.26%)
     

  • Hang Seng

    18,868.71
    -326.89 (-1.70%)
     

  • FTSE Bursa Malaysia

    1,629.18
    +7.09 (+0.44%)
     

  • Jakarta Composite Index

    7,222.38
    +36.34 (+0.51%)
     

  • PSE Index

    6,659.99
    +52.77 (+0.80%)
     

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Acumen Pharmaceuticals, Inc.
·1-min read
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc.

CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET).

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com